HEMARINA
Alexandre Garlaschelli is a professional with extensive experience in operational and production management within the biotechnology field. Currently serving as Responsable operationnel and Responsable de la production at HEMARINA since June 2016, Alexandre has previously held positions such as Ingénieur Procédés and ingénieur d'étude at CNRS IUEM from January 2014 to June 2016. Alexandre's earlier career includes a role as Responsable bioprocédés at seadev-fermensys from January 2006 to March 2012. Academic qualifications include a Diplôme d'ingénieur in Biotechnologies et microbiologie from Polytech Marseille and a DEUG in Science de la matière Biochimie from Université Claude Bernard Lyon 1.
This person is not in any teams
HEMARINA
Hemarina SA. is a privately held biotechnology company focused on the research, and development of oxygen-carriers for medical applications.Dr. Franck Zal, an expert in the field of invertebrate hemoglobin and oxygen transport, founded Hemarina after having spent more than fourteen years in academic research centers (CNRS, University ofCalifornia at Santa Barbara USA and University of Antwerpen, Belgium) studying the relationships between the structure and function of invertebrate respiratory pigment (annelid’s extracellular hemoglobin and crustacean hemocyanin). The discoveries arising from his research on extracellular hemoglobin coming from marine invertebrates and their effective oxygen transport system have been patented and published in numerous scientific journals and form the basis of Hemarina’s technologies.Hemarina’s approach to the development of oxygen transport agents is based on the observation of marine worms colonizing extreme environments and the study of their respiratory adaptations.Hemarina’s lead product, HbAm, is designed to deliver oxygen effectively and efficiently to tissues at risk of oxygen deprivation. Hemarina has already a passed panel of strong proof of concepts obtained during preclinical trials.